Europe Theranostics Market - 2024-2031
Europe Theranostics Market reached US$ 501.86 million in 2022 and is expected to reach US$ 1,104.22 million by 2031, growing with a CAGR of 10.60% during the forecast period 2026-2031.
The Europe Theranostics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Europe Theranostics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Disease
Both primary and secondary data sources have been used in the global Europe Theranostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Europe Theranostics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Europe Theranostics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Disease
- Oncology Diseases
- Neurology Diseases
- Cardiovascular Diseases
- Immunological Diseases
- Others
- Polymerase Chain Reaction (PCR)
- In-Situ Hybridization
- Immunohistochemistry
- Sequencing
- Hospitals
- Diagnostic Laboratories
- Others
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Europe Theranostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing research & development
4.1.1.2. Rising novel companion diagnostic product launches.
4.1.2. Restraints:
4.1.2.1. High costs associated with theranostics products are expected to hamper the market growth.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY DISEASE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
7.1.2. Market Attractiveness Index, By Disease
7.2. Oncology Diseases
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Neurology Diseases
7.4. Cardiovascular Diseases
7.5. Immunological Diseases
7.6. Others
8. BY TECHNOLOGY
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Polymerase Chain Reaction (PCR)
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. In-Situ Hybridization
8.4. Immunohistochemistry
8.5. Sequencing
9. BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Laboratories
9.4. Others
10. BY COUNTRY
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Country
10.1.2. Market Attractiveness Index, By Country
10.2. Germany
10.2.1. Introduction
10.2.2. Key Country-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.3. U.K.
10.3.1. Introduction
10.3.2. Key Country-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.4. France
10.4.1. Introduction
10.4.2. Key Country-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.5. Italy
10.5.1. Introduction
10.5.2. Key Country-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.6. Spain
10.6.1. Introduction
10.6.2. Key Country-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.7. Rest of Europe
10.7.1. Introduction
10.7.2. Key Country-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. COMPANY PROFILES
12.1. GE Healthcare
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. F. Hoffmann La Roche
12.3. Illumina Inc.
12.4. Owlstone Medical
12.5. Agilent Technologies
12.6. Qiagen NV
12.7. Foundation Medicine
12.8. Leica Biosystems Nussloch GmBH
12.9. Abbott Laboratories
12.10. Beckman Coulter.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing research & development
4.1.1.2. Rising novel companion diagnostic product launches.
4.1.2. Restraints:
4.1.2.1. High costs associated with theranostics products are expected to hamper the market growth.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY DISEASE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
7.1.2. Market Attractiveness Index, By Disease
7.2. Oncology Diseases
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Neurology Diseases
7.4. Cardiovascular Diseases
7.5. Immunological Diseases
7.6. Others
8. BY TECHNOLOGY
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Polymerase Chain Reaction (PCR)
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. In-Situ Hybridization
8.4. Immunohistochemistry
8.5. Sequencing
9. BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Laboratories
9.4. Others
10. BY COUNTRY
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Country
10.1.2. Market Attractiveness Index, By Country
10.2. Germany
10.2.1. Introduction
10.2.2. Key Country-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.3. U.K.
10.3.1. Introduction
10.3.2. Key Country-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.4. France
10.4.1. Introduction
10.4.2. Key Country-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.5. Italy
10.5.1. Introduction
10.5.2. Key Country-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.6. Spain
10.6.1. Introduction
10.6.2. Key Country-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.7. Rest of Europe
10.7.1. Introduction
10.7.2. Key Country-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. COMPANY PROFILES
12.1. GE Healthcare
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. F. Hoffmann La Roche
12.3. Illumina Inc.
12.4. Owlstone Medical
12.5. Agilent Technologies
12.6. Qiagen NV
12.7. Foundation Medicine
12.8. Leica Biosystems Nussloch GmBH
12.9. Abbott Laboratories
12.10. Beckman Coulter.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us
